Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome

Neuro-Oncology

Volumn 16, Issue 2, 2014, Pages 280-291

  Jensen, Randy L ^a,e   Mumert, Michael L ^a   Gillespie, David L ^a,e   Kinney, Anita Y ^b,e   Schabel, Matthias C ^c,d   Salzman, Karen L ^a,e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Division of Epidemiology   (United States)

^c Utah Center for Advanced Imaging Research   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF UTAH   (United States)

Author keywords

DCE MRI; HIF 1; hypoxia; vascularity; VEGF

Indexed keywords

CARBONATE DEHYDRATASE IX; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD VOLUME; BRAIN EDEMA; BRAIN HYPOXIA; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CAPILLARY DENSITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SCANNER; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PILOT STUDY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SUSCEPTIBILITY WEIGHTED IMAGING; TREATMENT OUTCOME; TUMOR BLOOD FLOW; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR NECROSIS; TUMOR VASCULARIZATION; YOUNG ADULT;

DCE-MRI; HIF-1; HYPOXIA; VASCULARITY; VEGF.;

ADULT; AGED; ANOXIA; CELL PROLIFERATION; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; GLIOMA; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84893148315     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not148     Document Type: Article

References (61)

1. Jain RK. Determinants of tumor blood flow: a review. Cancer Res. 1988; 48(10):2641-2658.
2. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. J Neuro-oncol. 2000;50(1-2):99-108.
3. Knisely JP, Rockwell S. Importance of hypoxia in the biology and treatment of brain tumors. Neuroimag Clin N Am. 2002;12(4): 525-536.
4. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61(3): 215-225; discussion 226-229.
5. Yetkin FZ, Mendelsohn D. Hypoxia imaging in brain tumors. Neuroimag Clin N Am. 2002;12(4):537-552.
6. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56(19):4509-4515.
7. Bernsen HJ, Rijken PF, Peters H, et al. Hypoxia in a human intracerebral glioma model. J Neurosurg. 2000;93(3):449-454.
8. Rockwell S. Oxygen delivery: implications for the biologyand therapy of solid tumors. Oncol Res. 1997;9(6-7):383-390.
9. Flynn JR, Wang L, Gillespie DL, et al. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer. 2008;113(5):1032-1042.
10. Petrella JR, Provenzale JM. MR perfusion imaging of the brain: techniques and applications. AJR Am J Roentgenol. 2000;175(1): 207-219.
11. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology. 1994;191(1):41-51.
12. Cha S, Knopp EA, Johnson G,Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibilityweighted echo-planar perfusion MR imaging. Radiology. 2002;223(1): 11-29.
13. Pauliah M, Saxena V, Haris M, Husain N, Rathore RK, Gupta RK. Improved T(1)-weighted dynamic contrast-enhanced MRI to probe microvascularity and heterogeneity of human glioma. Magn Reson Imag. 2007;25(9):1292-1299.
14. Singh A, Haris M, Rathore D, et al. Quantification of physiological and hemodynamic indices using T(1) dynamic contrast-enhanced MRI in intracranial mass lesions. J Magn Reson imag. 2007;26(4):871-880.
15. HarisM,Gupta RK,SinghA, et al.Differentiation of infectivefromneoplastic brain lesions by dynamic contrast-enhanced MRI. Neuroradiology. 2008; 50(6):531-540.
16. Haris M, Kumar S, Raj MK, et al. Serial diffusion tensor imaging to characterize radiation-induced changes in normal-appearing white matter following radiotherapy in patients with adult low-grade gliomas. Radiat Med. 2008;26(3):140-150.
17. Awasthi R, Verma SK, Haris M, et al. Comparative evaluation of dynamic contrast-enhanced perfusion with diffusion tensor imaging metrics in assessment of corticospinal tract infiltration in malignant glioma. J Comput Assist Tomogr. 2010;34(1):82-88.
18. Fisher MJ, Adamson PC. Anti-angiogenic agents for the treatment of brain tumors. Neuroimag Clin N Am. 2002;12(4):477-499.
19. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med. 2003;9(6):713-725.
20. Aronen HJ, Perkio J. Dynamic susceptibility contrast MRI of gliomas. Neuroimag Clin N Am. 2002;12(4):501-523.
21. Covarrubias DJ, Rosen BR, Lev MH. Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist. 2004;9(5):528-537.
22. LawM, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusionMRimaging with glioma grade. AJNRAmJ Neuroradiol. 2004; 25(5):746-755.
23. Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Int Med. 2003; 138(8):659-668.
24. Kietzmann T, Krones-Herzig A, Jungermann K. Signaling cross-talk between hypoxia and glucose via hypoxia-inducible factor 1 and glucose response elements. Biochem Pharmacol. 2002;64(5-6): 903-911.
25. Lal A, Peters H, St Croix B, et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst. 2001;93(17):1337-1343.
26. Sondergaard KL, Hilton DA, Penney M, Ollerenshaw M, Demaine AG. Expression of hypoxia-inducible factor 1alpha in tumours of patients with glioblastoma. Neuropathol Appl Neurobiol. 2002;28(3):210-217.
27. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000;88(11):2606-2618.
28. Zhong H, Simons JW. Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun. 1999;259(3): 523-526.
29. Nordsmark M, Alsner J, Keller J, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer. 2001;84(8):1070-1075.
30. Beasley NJ, Leek R, Alam M, et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002;62(9):2493-2497.
31. Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007;26(2):241-248.
32. Schabel MC, DiBella EV, Jensen RL, Salzman KL. A model-constrained Monte Carlo method for blind arterial input function estimation in dynamic contrast-enhanced MRI: II. In vivo results. Phys Med Biol. 2010;55(16):4807- 4823.
33. SchabelMC,MorrellGR.UncertaintyinT(1)mappingusingthevariableflip anglemethod with two flip angles. Phys Med Biol. 2009;54(1):N1-N8.
34. Schabel MC, Parker DL. Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences. PhysMed Biol. 2008;53(9):2345-2373.
35. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Investigat Radiol. 2005;40(11): 715-724.
36. Schabel MC. A unified impulse response model for DCE-MRI. Magn Res Med. 2012;68(5):1632-1646.
37. St Lawrence K, Verdecchia K, Elliott J, et al. Kinetic model optimization for characterizing tumour physiology by dynamic contrast-enhanced near-infrared spectroscopy. Phys Med Biol. 2013;58(5):1591-1604.
38. Barajas RF Jr., Phillips JJ, Parvataneni R, et al. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro-Oncology. 2012;14(7):942-954.
39. Jensen RL. Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus. 2006;20(4):E24.
40. Jensen RL, Ragel BT, Whang K, Gillespie D. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol. 2006;78(3):233-247.
41. Rathi KR, Radotra BD, Khosla VK. Proliferative index in astrocytic tumours. Indian J Pathol Microbiol. 2007;50(4):754-758.
42. Zolota V, Tsamandas AC, Aroukatos P, et al. Expression of cell cycle inhibitors p21, p27, p14 and p16 in gliomas. Correlation with classic prognostic factors and patients outcome. Neuropathology. 2008; 28(1):35-42.
43. Chiba Y, Hashimoto N, Tsuboi A, et al. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients. Brain Tumor Pathol. 2010;27(1):29-34.
44. Zikou AK, Alexiou GA, Kosta P, et al. Diffusion tensor and dynamic susceptibility contrast MRI in glioblastoma. Clin Neurol Neurosurg. 2012;114(6):607-612.
45. Zikou AK, Kitsos G, Tzarouchi LC, Astrakas L, Alexiou GA, Argyropoulou MI. Voxel-based morphometry and diffusion tensor imaging of the optic pathway in primary open-angle glaucoma: a preliminary study. AJNR Am J Neuroradiol. 2012;33(91):128-134.
46. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996; 77(2):362-372.
47. Yao Y, Kubota T, Takeuchi H, Sato K. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology. 2005;25(3): 201-206.
48. Saksena S, Jain R, Narang J, et al. Predicting survival in glioblastomas using diffusion tensor imaging metrics. J Magn Reson Imaging. 2010; 32(4):788-795.
49. Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology. 2006;241(3):839-846.
50. Henry PT, Rajshekhar V. Post-traumatic malignant glioma: case report and review of the literature. Br J Neurosurg. 2000;14(1):64-67.
51. Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol. 2002;178(3):711-716.
52. Tzika AA, Astrakas LG, Zarifi MK, et al. Spectroscopic and perfusion magnetic resonance imaging predictors of progression in pediatric brain tumors. Cancer. 2004;100(6):1246-1256.
53. LaViolette PS, Cohen AD, Prah MA, et al. Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. Neuro Oncol. 2013;15(4):442-450.
54. Zacharaki EI, Morita N, Bhatt P, ORourke DM, Melhem ER, Davatzikos C. Survival analysis of patients with high-grade gliomas based on data mining of imaging variables. AJNR Am J Neuroradiol. 2012;33(6): 1065-1071.
55. Najafi M, Soltanian-Zadeh H, Jafari-Khouzani K, Scarpace L, Mikkelsen T. Prediction of glioblastoma multiform response to bevacizumab treatment usingmulti-parametric MRI. PLoS One. 2012;7(1):e29945.
56. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF.MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005;26(10):2466-2474.
57. OConnor JP, Jayson GC. Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? Clin Cancer Res. 2012;18(24): 6588-6598.
58. Awasthi R, Rathore RK, Soni P, et al. Discriminant analysis to classify glioma grading using dynamic contrast-enhanced MRI and immunohistochemical markers. Neuroradiology. 2012;54(3): 205-213.
59. Croteau D, Scarpace L, HearshenD, et al.Correlationbetweenmagnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery. 2001;49(4):823-829.
60. Chung C, Jalali S, Foltz W, et al. Imaging Biomarker Dynamics in an Intracranial Murine Glioma Study of Radiation and Antiangiogenic Therapy. Int J Radiat Oncol Biol Phys. 2013;85(3):805-812.
61. Kong DS, Kim ST, Kim EH, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol. 2011;32(2): 382-387.